Insulin drugs refer to medications that used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amounts of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The main product types of insulin drugs are prandial insulins, basal insulins, premixed insulins, and other insulins. A meal is referred to as a prandial. Postprandial (from post prandium) refers to the time after a meal, whereas preprandial refers to the time before a meal. The drugs are classified into branded drugs and generic drugs that are distributed by hospital pharmacies, retail pharmacies, drug stores, and others. The various applications include type II diabetes, type I diabetes, gestational diabetes, and prediabetes. The insulin drugs market research report is one of a series of new reports from The Business Research Company that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry. This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global insulin drugs market size will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global insulin drugs market size is expected to grow to $53.41 billion in 2027 at a CAGR of 10.0%. Changing lifestyles are leading to a higher prevalence of diabetes. This is expected to drive the demand for diabetes drugs during the forecast period. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes. According to a study, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period. High costs and long payback periods for investment in new diabetes drugs negatively impacted the market during the forecast period. The costs for drug approval processes that include multiple phases of clinical trials and screening processes with regulatory bodies such as the US FDA are very high. According to a study published in the journal JAMA, the cost of bringing a new drug from its conception to shelves was about $2.8 billion in 2020. These high costs and uncertainty regarding return on investments for drug development limited the investments by pharmaceutical companies in the development of new diabetic drugs, thus limiting the growth of the market during the historic period. There is an increasing trend of mergers and acquisitions for new formulations in the Insulin market and companies are investing in the development of new medicines in the insulin drugs market. For example, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool. This resulted in the turning off of one of the genes which were responsible for causing diabetes. This effectively decreased beta cell death and increased insulin production in the pancreas. Insulin maker, Novo Nordisk has developed a diabetes pill and planned to launch it in India by February 2022. This pill belongs to a blockbuster class of drugs, glucagon-like peptide-1 (GLP-1s) that stimulate insulin production. The new drug is expected to generate about $5 billion in annual sales. In July 2021, Eli Lilly and Company, a US-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of human drugs, acquired Protomer Technologies Inc. for an amount of $1 billion. Through this acquisition, Lilly enhances its capabilities to make the lives of diabetes patients better, and we're still committed to offering practical solutions, such as advancements in insulin therapy. The development of glucose-sensing insulin, which has the potential to significantly enhance both the therapeutic efficacy and safety of insulin therapy, is the next step in diabetes care. Protomer Technologies Inc. is a US-based pre-clinical stage biotechnology company pioneering in research and technology development for the treatment of metabolic disorders. Major players in the insulin drugs market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog, Actrapid, Admelog, Novolin/Actrapid/Insulatard, Ryzodeg, Sanofi, Soliqua/Suliqua, Toujeo, Tresiba, and Xultophy. North America was the largest region in the insulin drugs market in 2022. The Middle East is expected to be the largest growing region in the global insulin drugs market during the forecast period. The regions covered in the global insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The insulin drugs market consists of sales of rapid-acting insulin, short-acting insulin, and mixed insulin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global insulin drugs market is segmented - 1) By Product Type: Prandial Insulins, Basal Insulins, Premixed Insulins, Other Insulins 2) By Application: Type II Diabetes, Type I Diabetes, Gestational Diabetes, Prediabetes 3) By Drug Classification: Branded Drugs, Generic Drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drugs Stores, Other Distribution Channels

Insulin patch pumps are small, computerized devices with pre-programmed delivery of insulin dosage to a diabetic patient to conveniently manage their blood sugar. An insulin patch pump is often attached to a strap under the garments, in a pocket, on the waist belt, and with an adhesive patch on the stomach or arm of the patient. The main types of insulin patch pumps are traditional insulin pumps, smart insulin pump and disposable insulin pumps. The traditional insulin pumps are a small device used to delivers insulin through a small plastic tube. The device continually pumps insulin throughout the day and night. Before meals, it can also supply insulin more quickly. These mode of delivery includes basal and bolus. The pumps come in two types namely tethered pump and patch pump to treat patients with type 1 diabetes and type 2 diabetes. These are mainly used in hospital, clinics, laboratories, and others. The insulin patch pumps market research report is one of a series of new reports from The Business Research Company that provides insulin patch pumps market statistics, including insulin patch pumps industry global market size, regional shares, competitors with a insulin patch pumps market share, detailed insulin patch pumps market segments, market trends and opportunities, and any further data you may need to thrive in the insulin patch pumps industry. This insulin patch pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global insulin patch pumps market size grew from $1.18 billion in 2022 to $1.28 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The insulin patch pumps market size is expected to grow to $1.83 billion in 2027 at a CAGR of 9.3%. The rising prevalence of diabetes across the globe is expected to drive the growth of the insulin patch pumps market in the forecast period. Diabetes is a major disease around the world, and it is caused due to many reasons by lifestyle and food habits. Insulin patch pumps help in the convenient delivery of insulin directly into the body and many people with diabetes find insulin pumps to be more convenient than insulin injections. The rising prevalence of diabetes leads to a need for insulin patch pumps. For instance, according to the International Diabetes Federation, in 2021, around 537 million people in the age group between 20 to 79 years are suffering from diabetes and these numbers are estimated to reach 643 million by 2030. In 2021, around 6.7 million people died due to diabetes. Therefore, the rising prevalence of diabetes across the globe will propel the growth of the insulin patch pumps market. Integration of the advanced technologies in insulin patch pumps is the key trend gaining popularity in the insulin patch pumps market. Insulin patch pumps are being integrated with the advanced technologies such as integration with a smartphone and enabling automation in insulin delivery. Continuous glucose monitors and traditional insulin pumps are evolving into smarter devices that can automate insulin delivery. These devices offer convenient and easy-to-use features while reducing manual intervention for insulin delivery. For instance, in January 2022, Insulet Corporation, a US-based innovative medical device company, announced the FDA clearance of its Omnipod 5 automated Insulin delivery system for people with type 1 diabetes aged 6 years and older. It is the first and only tubeless automated insulin delivery system with compatible smartphone control. It makes it easier than ever to manage glucose with no multiple daily injections, no tubes, and zero fingersticks to help simplify life with diabetes. In April 2020, Zealand Pharma, a Danish biotechnology research company, acquired Valeritas for $23 million. With this acquisition, Zealand Pharma aims to transform into a fully integrated biotech company with an established footprint in the US diabetes market and provide the V-Go wearable insulin delivery device to help people manage their diabetes. Valeritas is a US-based medical technology company offering innovative drug delivery solutions. Major players in the insulin patch pumps market are Cellnovo, Insulet Corporation, Medtronic PLC, Tandem Diabetes Care Inc., Hoffmann-La-Roche AG, Cequr SA, Animus Corp., Ypsomed, Abbott Laboratories Inc., Becton, Dickinson and Company, Braun Melsungen AG, Sanofi, Eoflow, Johnson & Johnson, Zealand Pharma, and Debiotech SA. North America was the largest region in the insulin patch pumps market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin patch pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the insulin patch pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The insulin patch pumps market consist of sales of insulin reservoir, pumping, mechanism and cannula. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global insulin patch pumps market is segmented - 1) By Type: Traditional Insulin Pumps, Smart Insulin Pump, Disposable Insulin Pumps 2) By Mode: Basal, Bolus 3) By Pump Type: Tethered Pump, Patch Pump 4) By Application: Type 1 Diabetes, Type 2 Diabetes 5) By End-User: Hospital, Clicins, Laboratories, Other End-Users

Smart insulin pens are insulin delivery devices that keep track of the volume, time, and type of dosage. These devices may also perform tasks such as generating reports to be shared with healthcare professionals. The main types of smart insulin pens are first-generation pens and second-generation pens (Bluetooth enabled, USB connected). The second-generation smart insulin pens are devices that are engineered with Bluetooth or USB features to enable closer monitoring. The smart insulin pens are either prefilled or reusable that is used to treat type 1 diabetes and type 2 diabetes. The various end-users of smart insulin pens are hospitals and clinics, ambulatory surgical centres, and home care settings. The smart insulin pens market research report is one of a series of new reports from The Business Research Company that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart insulin pens market size will grow from $0.09 billion in 2022 to $0.10 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart insulin pens market size is expected to grow to $0.12 billion in 2027 at a CAGR of 6.2%. An accurate dose of insulin can be achieved than a vial or a syringe with an insulin pen. For kids who need to take insulin during school time and visually impaired diabetic patients, an accurate dose of insulin can even be pre-set over the dosage dial which helps inaccurate delivery of dose at the time of injection. Echo Plus by Novo Nordisk which is a pediatric-friendly insulin pen allows even half-unit dosing with a maximum of 30 units. HumaPen Luxura HD from Lilly allows the delivery of insulin in half-unit increments and NovoPen Junior - Insulin Pen by Novo Nordisk can deliver highly accurate doses of insulin and finely adjusts small doses even half-unit increments. The accurate adjustments and delivery of doses of insulin can avoid either over-dosing or low-dosing of the drug which is expected to increase the demand for smart insulin pens and drive the market growth. Diabetics may be prescribed two types of insulin for better control over blood glucose levels. They usually prefer pre-mixed insulin (combination) or a method in which the insulin doses could be mixed and once puncture is necessary to deliver the different types of insulin doses required. Multiple punctures for the insulin delivery can lead to poor adherence to the medication which in turn results in poor glycemic control. A study published states that poor glycemic control (A1c>7%) was reported in 68% of respondents and there was an association between A1c >7% and poor adherence levels. Dislike towards injection to a large extent and needle phobia can result in poor adherence levels. It is estimated that over 10% of the population has needle phobia. These factors can reduce the adherence of smart insulin pens where two types of insulin can't be mixed and result in multiple needle punctures which thereby affect the purpose of the insulin being administered which is expected to hinder the market growth. The next generation of smart insulin pens goes far beyond memory storage. They help in calculating personalized doses, track glucose continuously, and connect with apps of smartphones to visualize the data. In September 2020, Medtronic plc introduced InPen™ that is integrated with Guardian Connect™ CGM data to manage their diabetes. It is the only FDA_cleared smart insulin pen for people on multiple daily injections. This enhances the ease of usage of smart insulin pens which is expected to boost the market. In February 2020, Senseonics a US-based medical technology company that primarily focuses on the design, development, and commercialization of glucose monitoring products announced a partnership with Companion Medical. The partnership will benefit both companies by integrating Eversense® CGM System with the InPen™ smart system for accurate insulin delivery. Companion Medical is a US-based company that aims at achieving desirable diabetes outcomes and manufactured InPen™ which is the US first FDA-approved insulin pen. Major players in the smart insulin pens market are Companion Medical, Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co. Ltd., Emperra GmbH E-Health Technologies, Digital Medics Pvt Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Jiangsu Delfu medical device Co. Ltd., and Bigfoot Biomedical. North America was the largest region in the smart insulin pens market in 2022. Western Europe was the second largest region in the global smart insulin pens market. The regions covered in the global smart insulin pens market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart insulin pens market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart insulin pens market is segmented - 1) By Type: First Generation Pens, Second Generation Pens (Bluetooth Enabled, USB Connected) 2) By End User: Hospitals & Clinics, Ambulatory Surgical Centres, Home Care Settings 3) By Usability: Prefilled, Reusable 4) By Application: Type 1 Diabetes, Type 2 Diabetes

Diabetes care devices are used to monitor and control blood glucose levels in diabetic patients. The main types of diabetes care devices are blood glucose test strips, insulin pens, syringes, pumps and injectors, lancing devices and equipment, continuous glucose monitoring devices and equipment, and blood glucose meters. Insulin pens are injection devices with a needle that delivers insulin into the subcutaneous tissue. The type of expenditures is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The diabetes care devices market research report is one of a series of new reports from The Business Research Company that provides diabetes care devices market statistics, including diabetes care devices industry global market size, regional shares, competitors with a diabetes care devices market share, detailed diabetes care devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care devices industry. This diabetes care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global diabetes care devices market grew from $58.63 billion in 2022 to $62.94 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diabetes care devices market is expected to grow to $80.06 billion in 2027 at a CAGR of 6.2%. Busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes. Long working hours, limited physical activity, and unhealthy eating and drinking habits are major causes of diabetes. For instance, according to WHO data 2021, more than 95% of people with diabetes have type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes. For instance, according to IDF data 2021, nearly 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. These factors are expected to aid the market growth in the forecast period. The diabetes care devices market is expected to be limited by the high cost of the equipment, especially in low-income countries, where the cost related to diabetes devices is very high, despite insurance coverage. For example, in the US all the expenses related to diabetes treatment, which includes diabetes care devices can reach $1,000 a month. Thus, high costs associated with diabetes care devices and their accessories are likely to impede the market growth going forward. Pharmaceutical companies are investing in developing and commercializing glucose-responsive insulins (GRIs), providing significant opportunities for the development of new types of insulin delivery devices. For example, Novo Nordisk, a Danish pharmaceutical company, has planned to develop GRIs by acquiring UK biotech start-up Ziylo with an investment of $800 million. Companies such as Eli Lily and Sanofi have also planned research projects to develop GRIs. GRIs are 'smart' insulins that automatically activate or deactivate in response to changing glucose levels in the blood. They improve diabetes treatment efficacy and reduce the incidence of hyperglycemia and hypoglycemia. Major companies in the diabetes care devices market include Abbott Laboratories, Novo Nordisk, Medtronic Inc., Dexcom, Inc., F. Hoffmann-La Roche Ltd., Becton Dickinson, Insulet, Ypsomed, ConvaTec Group Plc, and B. Braun Group. North America was the largest region in the global diabetes care devices market in 2022. Western Europe was the second largest region in the global diabetes care devices market. The regions covered in the diabetes care devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diabetes care devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The diabetes care devices market consists of sales of blood glucose monitoring devices, insulin delivery devices, smart insulin pens and others that are used for monitor and treat diabetes patient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global diabetes care devices market is segmented - 1) By Type: Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables Subsegments Covered: Glucose Dehydrogenase, Glucose Oxidase, Pens, Injectors And Pumps, Syringes

Digital diabetes management refers to using electronic medical solutions to monitor, analyze, and manage diabetics remotely. People with diabetes or those who are at risk for developing it can improve their health outcomes by successfully managing their condition on their own with the help of digital diabetes management. The main types of products and services in digital diabetes management are devices, application, data management software & platforms, services. A data management platform (DMP) is a piece of software that collects and manages data. They enable companies to create audience segments that can then be utilized to target certain individuals and settings in online advertising campaigns. The different types of devices include handheld devices, wearable devices and used in various sectors such as self or home healthcare, hospitals and specialty diabetes clinics, others. The digital diabetes management market research report is one of a series of new reports from The Business Research Company that provides digital diabetes management market statistics, including digital diabetes management industry global market size, regional shares, competitors with a digital diabetes management market share, detailed digital diabetes management market segments, market trends and opportunities, and any further data you may need to thrive in the digital diabetes management industry. This digital diabetes management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digital diabetes management market size will grow from $10.82 billion in 2022 to $13.25 billion in 2023 at a compound annual growth rate (CAGR) of 22.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global digital diabetes management market size is expected to grow to $30.11 billion in 2027 at a CAGR of 22.8%. The increasing prevalence of diabetes is projected to propel the demand for digital diabetes management devices and related services, thereby increasing the demand for the market. Diabetes is a leading cause of death, with 30% of loss of life expectancy coming from the diagnosis of diabetes. In 2021, according to the International Diabetes Federation, a total of 537 million individuals (20-79 years old) worldwide had diabetes and according to projections, there will be 643 million diabetics worldwide by 2030 and 783 million by 2045. Data security is a major challenge limiting the growth of the digital diabetes management market. Data safety is necessary to maintain integrity and confidentiality. A lack of accurate flow of information and commands is likely to compromise the function of digital diabetes devices and may put patients or users at the risk of health complications. For instance, according to Hippa Journal, the official publication of the American Health Information Management Association, the Office for Civil Rights (OCR) of the Department of Health and Human Services (HHS) received 347 reports of healthcare data breaches involving 500 or more records between January 1, 2022, and June 30, 2022. Several companies are increasing attention on developing design-focused and AI-powered connected apps to enhance the user experience, which is gaining significant popularity in the digital diabetes management market. Key companies operating in the digital diabetes management market including OneDrop, Ascencia, and Dario are increasing their focus on developing their products as stylish gadgets rather than medical devices. For instance, Medtronic plc and IBM Watson Health announced the launch of AI-powered Sugar.IQ smart diabetes management app, designed to improve and simplify daily diabetes management. In April 2020, OneDrop, a consumer diabetes management platform, announced the acquisition of assets, IP, and certain staff of Sano Intelligence Inc., an innovator in health sensing technology, for an undisclosed amount. OneDrop and Sano Intelligence shared a vision of transforming traditional healthcare into preventive and proactive self-care. The companies are expected to integrate Sano’s silicon sensing technology into a painless silicon-based health sensing platform for use across multiple conditions, which is a personalized solution for a rapidly growing health issue. Sano Intelligence, Inc. was founded in 2011 and is a manufacturer of non-invasive connected CGM patch. Major players in the digital diabetes management market are Bayer AG, Medtronic, Roche Diagnostics, Dexcom, Inc., Abbott Laboratories, Ascensia Diabetes Care, Insulet Corporation, B. Braun Melsungen AG, Tandem Diabetes Care and LifeScan Inc. North America was the largest region in the digital diabetes management market in 2022. Western Europe was the second largest region in the global digital diabetes management market. The regions covered in the global digital diabetes management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digital diabetes management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digital diabetes management market consists of revenue generated by the companies offering devices and services that manage blood glucose levels in the human body. These devices play a vital role in the care of diabetes patients with the management of patients' blood glucose levels and controlling their conditions. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digital diabetes management market is segmented - 1) By Product & Service: Devices, Application, Data Management Software & Platforms, Services 2) By Device Type: Handheld Devices, Wearable Devices 3) By End User: Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, Other End Users

Lancing devices and equipment are used to prick the skin to obtain blood samples for testing glucose levels. The main products of lancing devices and equipment are safety lancets and standard lancets. Safety lancets are sterile, single-use devices intended for capillary blood sampling. The lancing devices and equipment types are reusable and disposable that are available at various penetration depths such as 0.8mm-1mm, 1.1mm- 1.5mm, 1.6mm-2.0mm, and others. The end-users are hospitals and clinics, homecare and home diagnostics, diagnostic centres and medical institutions, research and academic laboratories, and others. The lancing devices and equipment market research report is one of a series of new reports from The Business Research Company that provides lancing devices and equipment market statistics, including lancing devices and equipment industry global market size, regional shares, competitors with a lancing devices and equipment market share, detailed lancing devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the lancing devices and equipment industry. This lancing devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global lancing devices and equipment market size will grow from $0.5 billion in 2022 to $0.58 billion in 2023 at a compound annual growth rate (CAGR) of 16.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The lancing devices and equipment market size is expected to grow to $1.11 billion in 2027 at a CAGR of 17.5%. The rising prevalence of diabetes is driving the market for lancing devices and equipment as more people depend on lancing devices to test blood glucose levels. Lancing devices are used by diabetics to obtain samples of blood for testing glucose levels in it. According to the International Diabetes Federation, in 2021, around 537 million adults had diabetes and the number is expected to reach 783 million by 2045. This growth in the number of diabetic patients is expected to increase the demand for lancing devices and equipment, thereby driving the market growth. Recalls of defective lancing devices are acting as a restraint on the lancing devices and equipment market. A product recall is done by the manufacturer or regulatory body as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. Lancing devices and equipment penetrate the skin and come in direct contact with blood inside the body. Any defect in the product can infect the blood causing risk to the patient's life. For instance, the ACCU-CHECK FastClix Lancing Device by Roche Diagnostics Operations Inc. was recalled by the Food and Drug Administration (FDA) as the needle of the lancet utilized in a finger stick may not completely retract back into the lancet drum as it was intended to. Such recalls discourage product use and affect the growth of the market. Lancing device manufacturers are increasingly using custom vacuum technology in lancing devices to minimize pain from poking. Lancing devices that use this technology create a shallow puncture on the skin without hitting the deeper pain nerves and blood is pulled up by the vacuum. For example, the Genteel Lancing Device is a vacuum blood drawing lancing device that draws blood from the capillaries and can be used on different sites on the body apart from fingers. Lancing devices and equipment manufacturers are governed by regulatory bodies such as the Food and Drug Administration Act (FDA) in the USA. For instance, in the USA, Section 510(k) of the Food, Drug, and Cosmetic Act requires manufacturers of lancing devices to register their device with the FDA and notify their intent to market the device at least 90 days before the actual marketing of the device. This period of 90 days allows FDA to classify the device among three prescribed classes (Class I, II, or III). The FDA also laid down regulations regarding the application of section 510(K) in case of advancements, or changes made to the lancing device. In September 2021, B. Braun Melsungen AG, a German medical and pharmaceutical device company acquired Sterinova Inc for an undisclosed amount. This acquisition of Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG. Sterinova Inc is a Canada-based company that develops, manufactures, and distributes ready-to-use sterile injectable products in syringes and premix bags. Major players in the lancing devices and equipment market are Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, F. Hoffmann-La Roche AG, LifeScan, Ascensia Diabetes Care, Becton Dickinson, Bayer AG, Medtronic, and ARKRAY. North America was the largest region in the global lancing devices and equipment market in 2022. Western Europe was the second-largest region in the lancing devices and equipment market. The regions covered in the global lancing devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the lancing devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The lancing devices and equipment market consist of sales of safety lancets and standard lancets, flake lancets And fixed depth lancet. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global lancing devices and equipment market is segmented - 1) By Product: Safety Lancets, Standard Lancets 2) By Type: Reusable, Disposable 3) By End User: Hospitals and Clinics, Homecare and Home Diagnostics, Diagnostic Centres and Medical Institutions, Research and Academic Laboratories, Other End User 4) By Penetration Depth: 0.8mm-1mm, 1.1mm- 1.5mm, 1.6mm-2.0mm, Other Penetration Depths

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drug delivery devices market size is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the global drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices